By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at


August 7, 2007


Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su

CEO: David Schenkein

CMO (Medical): Chris Bowden

CSO (Scientific): Scott Biller


Please click here for Agios job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Agios
Symbol: AGIO

Company News
Agios (AGIO) Reports Second Quarter 2017 Financial Results 8/8/2017 12:51:35 PM
Agios (AGIO), Celgene (CELG) Win Early FDA Approval for New Cancer Drug 8/1/2017 10:05:56 AM
Agios (AGIO) To Webcast Conference Call Of Second Quarter 2017 Financial Results On August 8, 2017 7/28/2017 8:22:24 AM
Agios (AGIO) Release: New Data From Phase I/II Trial Of Oral IDHIFA (Enasidenib) Demonstrate Durable Complete Responses In Patients With IDH2 Mutant Relapsed Or Refractory AML 6/26/2017 11:06:35 AM
Agios (AGIO) Announces Updated Data From Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential As The First Disease-Modifying Treatment For Patients With Pyruvate Kinase Deficiency 6/26/2017 11:02:03 AM
Agios (AGIO) Presents Phase I Data From Dose-Escalation And Expansion Cohorts Of AG-120 (Ivosidenib) In Patients With IDH1 Mutant Positive Cholangiocarcinoma 6/6/2017 3:08:08 PM
Agios (AGIO) Appoints David Scadden, M.D., To The Board Of Directors 6/1/2017 12:37:35 PM
Agios (AGIO) To Present New Clinical Data From Its IDH Programs At ASCO 5/18/2017 10:55:47 AM
Thermo Fisher Scientific (TMO) Signs Development Agreement With Agios (AGIO) For Next-Generation Sequencing Oncology Companion Diagnostic In Cholangiocarcinoma 5/18/2017 6:43:44 AM
Agios (AGIO) Reports First Quarter 2017 Financial Results 5/4/2017 11:21:14 AM